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Abstract
Background: Human cytomegalovirus infection is associated with a variety of pathological conditions including
retinitis, pneumonia, hepatitis and encephalitis that may be transmitted congenitally, horizontally and parenterally
and occurs both as a primary infection and as reactivation in immunocompromised individuals. Currently, there
is a need for improved quantitative serological tests to document seropositivity with high sensitivity and
specificity.
Methods: Here we investigated whether luciferase immunoprecipitation systems (LIPS) would provide a more
quantitative and sensitive method for detecting anti-CMV antibodies. Four protein fragments of immunodominant
regions of CMV antigens pp150 and pp65 were generated as Renilla luciferase (Ruc) fusion proteins and used in
LIPS with two cohorts of CMV positive and negative sera samples previously tested by ELISA.
Results: Analysis of the antibody responses to two of these antigen fragments, pp150-d1 and pp150-d2, revealed
geometric mean antibody titers in the first cohort that were 100–1000 fold higher in the CMV positive sera
compared to the CMV negative samples (p < 0.0001) and infection status exactly matched the ELISA results for
the 46 samples of the first cohort (100% sensitivity and 100% specificity). Two additional antigen fragments, pp65-
d1 and pp65-d2 also showed robust antibody titers in some CMV-infected sera and yielded 50% and 96%
sensitivity, respectively. Analysis of a second cohort of 70 samples using a mixture of the 4 antigens, which
simplifies data collection and analysis, yielded values which correlated well with the sum of the values from the 4
separate tests (rs = 0.93, p < 0.00001). While comparison of the LIPS results from this second cohort with ELISA
showed 100% sensitivity, LIPS detected six additional CMV positive samples that were not detected by ELISA.
Heat map analysis revealed that several of the LIPS positive/ELISA negative samples had positive LIPS
immunoreactivity with 3–4 of the CMV antigens.
Conclusion: These results suggest that LIPS provides a highly robust and quantitative method for studying anti-
CMV antibodies and has the potential to more accurately document CMV infection than standard ELISA.
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Introduction
Cytomegalovirus (CMV) is the largest member of the her-
pesvirus family, with a genome of approximately 230 kb
encoding 160 genes [1]. Like several other herpes viruses,
CMV infection is widespread and its seroprevalence in
some lower socioeconomic communities can be greater
than 90% [2]. In the United States, approximately 60% of
the adult population is infected with CMV [3]. In most
cases, initial infection with CMV presents without any
overt symptoms. After primary infection, CMV infection
remains latent in the body for life, but can show sporadic
episodes of lytic activation. In immunocompromised
individuals, including HIV-infected patients, CMV infec-
tion and reactivation can lead to ocular infections,
encephalitis, and hepatitis [4]. CMV infection is also a
common cause of febrile illnesses and graft rejection in
transplant patients [5] and transfusion can lead to pri-
mary infection or reactivation of the virus [6]. CMV infec-
tion likely plays a role in vascular injury [7] and a variety
of neurological problems including Guillain Barré syn-
drome [4,8]. Moreover, unlike other herpes viruses, a
large number of CD4+ and CD8+ T-lymphocytes are ded-
icated to controlling CMV infection and studies have
shown that the levels of these CMV specific T cells may
decline during aging and illness [9]. CMV reactivation pre-
dicts morbidity and mortality in the elderly [10-12], in
immunocompromised patients [13-17] and even in
younger, immunocompetent individuals [18]. Given that
CMV infection plays an important role in the pathogene-
sis of many different human conditions, better and more
accurate methods are needed to diagnose and monitor
immune responses to this infection.
Currently quantitative PCR- and DNA-based tests are use-
ful for diagnosis and determining viral load [19]. How-
ever, understanding complex individual host responses to
CMV infection will require more sophisticated informa-
tion on disease status or processes than provided by cur-
rent serological tests. The most quantitative serological
immunoassays available to detect anti-CMV antibodies
are ELISAs that use whole cell viral CMV lysates or recom-
binant CMV proteins usually produced in bacteria [20-
22]. ELISAs employing CMV viral protein lysates contain
a heterogeneous mixture of antigenic and non-antigenic
proteins and have the potential to show cross-immunore-
activity with other herpes virus proteins. CMV proteins
produced in bacteria as recombinant antigens can yield
potential false signals and high backgrounds due to
immunoreactivity with E. coli contaminants. Further-
more, solid phase ELISAs employing either CMV viral pro-
tein lysates or recombinant proteins require serial
dilutions for semi-quantitative evaluation of antibodies
and miss many conformational epitopes resulting in a
limited dynamic range of detection. A more complicated
CMV avidity ELISA, requiring serial dilutions, is used to
distinguish primary verses long-term infection in longitu-
dinal samples, but has limited dynamic range [23].
In order to circumvent some of the problems with solid
phase ELISAs, we developed a liquid phase luciferase
immunoprecipitation systems (LIPS). This system utilizes
mammalian cell-produced, recombinant Renilla luciferase
fusion antigens for efficiently constructing and expressing
target antigens and quantitatively evaluating antibody
responses [24-30]. LIPS has shown improved diagnostic
performance compared to existing immunoassays for
detecting antibodies to a variety of infectious agents
[24,28-30] and has a wide dynamic range of detection
providing new tools to monitor drug treatment [30] and
sub-stratify disease states [28]. More recently, LIPS has
been shown to be superior to ELISA to detect and monitor
antibodies to herpes simplex virus (HSV)-1 and HSV-2
[31]. In the present study, LIPS was evaluated for its diag-
nostic performance in detecting anti-CMV antibodies.
Results
LIPS profiling of antibodies to four immunodominant CMV 
antigen fragments
We generated four different immunodominant fragments
of pp150 and pp65 as C-terminal Renilla luciferase (Ruc)
fusion proteins using the pREN2 vector [25]. Previously
described recombinant CMV protein fragments that were
used [32] included two immunodominant fragments of
pp150 spanning amino acids 502–692 (pp150-d1), and
859–1048 (pp150-d2) and two immunodominant frag-
ments of pp65 spanning amino acids 2–295 (pp65-d1),
and 312–561 (pp65-d2). These four constructs were then
expressed in Cos1 cells and the lysates were used in the
LIPS assay to evaluate a blinded sera cohort containing
CMV seronegative and seropositive samples previously
tested by ELISA. Following unmasking of the ELISA data,
analysis of the geometric mean titer (GMT) for each of
these antibody tests revealed that the CMV-positive sera
had 800 to 2000-fold higher antibody titers compared to
the CMV-negative sera (Figure 1). For example, in the
CMV-negative sera the GMTs for pp150-d1, pp150-d2,
pp65-d1 and pp65-d2 were 17; 140; 200; and 7 LU,
respectively, while the GMTs in CMV-positive sera were
markedly higher with values of 233,715; 297,680; 17,203;
and 137,002 LU, respectively. Despite a wide range of tit-
ers, the results were highly reproducible. For example, the
duplicate interassay LIPS tests for anti-pp150-d1 antibod-
ies had a coefficient of variation (CV) of 14%. These
results suggest that one benefit of the dynamic range of
the LIPS format is that reproducible antibody titer differ-
ences of 100–1000-fold can be detected in the CMV-neg-
ative verses CMV-positive sera without the need for serial
dilutions.Virology Journal 2009, 6:45 http://www.virologyj.com/content/6/1/45
Page 3 of 8
(page number not for citation purposes)
Receiver operator characteristics (ROC) analysis of each of
the tests demonstrated that the anti-pp150-d1, anti-
pp150-d2 and anti-pp65-d2 antibody tests had area under
the curve (AUC) values of 1.0, reflecting the very high sen-
sitivity and specificity of these tests. The anti-pp65-d2
antibody test was less useful with an AUC value of 0.84.
Using a cut-off value derived from the mean plus five SD
of the CMV negative samples, the pp150-d1 and pp150-
d2 tests showed 100% sensitivity (26/26) and 100% spe-
cificity (20/20) for detecting CMV positive samples. Using
this same cut-off criterion, the pp65-d1 test had 96% sen-
sitivity (25/26) and 100% specificity (20/20), while the
anti-pp65-d2 test demonstrated the least antigenicity with
54% sensitivity (14/26) and 100% specificity (20/20).
Interestingly, a borderline CMV positive sample detected
by ELISA was the single low positive outlier detected by
LIPS (Figure 1).
Detection of anti-pp150-d1 (A), anti-pp150-d2 (B), anti-pp65-d1 (C), anti-pp65-d2 (D) antibodies by LIPS in the first sera  cohort (n = 46) Figure 1
Detection of anti-pp150-d1 (A), anti-pp150-d2 (B), anti-pp65-d1 (C), anti-pp65-d2 (D) antibodies by LIPS in the 
first sera cohort (n = 46). Each symbol represents individual samples from CMV-negative and CMV-positive subjects deter-
mined by ELISA. Antibody titers in LU are plotted on a log10 scale. The dashed line, derived from the mean plus five SD of the 
antibody titer of the 20 uninfected samples, serves as the cut-off level for determining sensitivity and specificity for each individ-
ual antigen test. The long solid horizontal lines indicate the GMT of the antibody in each group and the vertical lines show the 
95% confidence intervals.
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In addition to analyzing the data from the four antigens
separately and to compare to the mixture of antigens ana-
lyzed in a second, independent cohort (see below), we
summed the antibody titers from the 4 individual tests
and used a 15,000 LU cutoff, which was derived from the
mean plus five standard deviations of the CMV negative
samples. In this analysis, the 26 CMV positive samples
detected in the individual tests were also detected in this
combined approach and the 20 CMV negative samples
again tested negative (Figure 2A). Together these results
suggest that the single antigen tests (especially the pp150-
d1 and pp150-d2 tests) and the combined results from
the four individual tests provide an extraordinarily sensi-
tive and specific method for profiling anti-CMV antibod-
ies to diagnose infection.
A four antigen mixture for profiling anti-CMV antibodies
Based on the results and cut-off values obtained in the first
serum set, the four separate CMV LIPS tests were used with
a new, second blinded cohort (n = 70 sera), which had
been previously evaluated by ELISA. Prior to unblinding,
we also analyzed these new sera for anti-CMV antibodies
using a LIPS mixture format, where all four antigens were
added together in a single well and processed simultane-
ously (Figure 2C). For comparison, the sum of the anti-
body titer results from the 4 separate antigen tests was also
calculated and plotted (Figure 2B). As shown in Figure 2B
and Figure 2C, the scatter plots of the sum titers of the 4
separate tests and the titer value of the four antigen mix-
ture are almost identical. Regression analysis revealed that
they closely correlated (Pearson R = 0.97, p < 0.00001). As
in the individual antigen tests, the geometric means were
over 100-fold greater in the CMV positive samples than
the CMV negative samples. Using a cut-off value of 15,000
LU previously determined from cohort 1, both formats
identified the same 41 potential positives and 29 poten-
tial negative samples (compare Figure 2B and 2C). Fol-
lowing unblinding, LIPS performance showed 100%
sensitivity (35/35) and 83% specificity (29/35) in detect-
ing the CMV infected sera in these two different LIPS assay
formats. While these results do not exactly match the
ELISA, the immunoreactivity profiles obtained from the
individual LIPS tests matches that of the mixture format
and further demonstrates the reproducibility and robust
nature of this system.
Log 10 transformed antibody titers and color coding were
used to create a heatmap to easily visualize the different
patient antibody responses toward the panel of antigens
and to gain further insight into discordant samples (Fig-
ure 3). In this graphic, obvious marked differences in
patient antibody responses to the antigen panel were
observed, which illustrates the heterogeneity in individual
humoral immune responses to the four individual CMV
antigens (Figure 3). As shown in Figure 3, many of the
ELISA positive/LIPS positive samples showed immunore-
CMV antibody titers to the sum of the four individual tests and using a mixture format Figure 2
CMV antibody titers to the sum of the four individual tests and using a mixture format. Antibody titers to the sum 
of the 4 antigens in the first cohort (A), second cohort (B) or using a 4 antigen mixture format in the second cohort (C). Each 
symbol represents individual samples from CMV-negative and CMV-positive samples determined by ELISA. In the case of the 
first cohort, the sum of the titer values from the four individual tests and a cut-off value of 15,000, showed 100% sensitivity and 
100% specificity. In the case of the second cohort, the LIPS tests from the sum of the 4 individual tests (B) or tested simultane-
ously as a mixture of four antigens (C) showed almost identical results; in each case, LIPS detected 6 samples that were ELSA 
negative. The solid horizontal lines indicate the GMT of the antibodies in each group and the vertical lines show the 95% confi-
dence intervals.
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Heat map representation of patient antibody profiles in second cohort to the four CMV antigens Figure 3
Heat map representation of patient antibody profiles in second cohort to the four CMV antigens. The titer val-
ues for each serum were log10 transformed and then the titer levels were color-coded as indicated by the log10 scale on the 
right, in which signal intensities range from green to red indicating low and high titers, respectively. The samples were rank 
ordered from highest to lowest based on the sum of the antibody titers to the four antigen panel. The samples on the left are 
from CMV infected sera and the samples in the middle panel represent the uninfected control sera. On the right are samples 
that were positive by the LIPS assay, but found to be negative according to the ELISA assay.
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activity to all four of the antigen fragments. One of the
ELISA positive samples (Figure 3, bottom of heatmap of
CMV positive samples) only showed positive LIPS immu-
noreactivity with the single anti-pp65-d1 antigen. Analy-
sis of the discordant ELISA negative/LIPS positive samples
showed that five of the six CMV ELISA negative samples
had highly positive anti-pp150-d1 antibody titers. Fur-
thermore, two of the ELISA negative samples were also
positive by LIPS for anti-pp65-d2 and four samples were
also positive for anti-pp65-d1 antibodies (Figure 3). It
should be noted that many of these ELISA negative/LIPS
positive samples showed markedly higher antibody titers
than many of the samples that were positive by both
ELISA and LIPS. Also, all of the discordant sera had low
background binding reactivity with a lysate containing
Ruc vector control protein suggesting that the observed
immunoreactivity was not due to "sticky sera" or non-spe-
cific binding to the Renilla luciferase protein backbone
(data not shown). Based on these results, it seems plausi-
ble that many of these discordant samples may represent
true CMV positive samples that were missed by ELISA.
Discussion
The use of LIPS allowed for highly quantitative measure-
ments of antibody titers to 4 different CMV protein frag-
ments. This simple modular assay system, where CMV
antigens were expressed as a series of Ruc fusion proteins
produced in Cos1 cells and then implemented in a liquid
phase assay, efficiently evaluated patient humoral
response to these different antigen fragments. Without
serial dilution, the LIPS format showed titer differences
spanning 100–1000 fold between the CMV-negative and
CMV-positive sera samples. Immunoreactivity of the sera
with multiple independent CMV antigen fragments, but
not with control Ruc protein, strongly suggests that these
samples contain anti-CMV antibodies detectable by LIPS.
Our strategy of using 4 independent antigen fragments
also allowed for independent assessment of antibodies
against different protein fragments. In addition to the
individual tests, we also used the LIPS assay in a mixture
format to simultaneously test the four different recom-
binant antigens and acquire the data as a single read out.
The ability to implement the test in a mixture format pro-
vides a simpler method of serologic detection. The fact
that the four antigen mixture closely correlated with the
data from the sum of the four individual antigen tests (R
= 0.97) further demonstrates the reproducibility of the
LIPS method and validates the results. The results from
the mixture format are also consistent with our previous
study of filarial infection where an antigen mixture was
superior to ELISA in detecting antibodies to this infectious
agent [30].
Compared to the ELISA, LIPS analysis of the two different
cohorts yielded an overall detection rate of 100% sensitiv-
ity and 89% specificity. In the first cohort, compared to
the ELISA, LIPS analysis yielded an overall detection rate
of 100% sensitivity and 100% specificity. In the second
cohort, six subjects in this cohort tested positive by LIPS,
but were negative by ELISA. While this variability may be
due to chance, it is important to note that five of these six
samples were positive for three of the four CMV antigens,
while the sixth sample was positive for only anti-pp65-d2
antibodies. One possible explanation for the discrepancy
of CMV serological status between these two tests may lie
in the different antigen sources used: the antigen source
for the CMV ELISA is a complex viral lysate, which con-
tains both antigenic and non-antigenic proteins that are
coated to the microtiter plate, while the LIPS assay uses
recombinant immunodominant CMV antigenic frag-
ments of about 250 amino acids produced in mammalian
cells and employed in a liquid phase assay. It is possible
that ELISA negative/LIPS positive samples may represent
early CMV infection, because immunodominant epitopes
were used, which can detect low titer antibody from early
infection better than ELISA using a crude lysate [30].
Therefore, it is possible if not probable, that these discord-
ant samples represent true CMV positive samples that can-
not be detected by ELISA. Consistent with this possibility,
in another comparative study, LIPS detected anti-HSV-2
antibodies better than an ELISA and exactly matched the
results of Western blot analysis [31]. Furthermore, several
reports have shown that ELISA formats using viral lysates
can miss CMV positive samples [8,32].
The ability to profile many different CMV antigens by this
robust and facile approach may be useful for understand-
ing host responses in different CMV-related diseases and
for vaccine monitoring. In a previous study, LIPS detected
relatively higher anti-HSV-2-specific glycoprotein anti-
bodies in HSV-2 positive verses HSV-1 positive samples
[31]. Based on a recent study that showed CMV strains
could be distinguished by serology [33], LIPS screening of
strain-specific glycoproteins from different CMV species
might be a useful tool for genotyping studies. In sum, our
current panel of four antigen fragments used either indi-
vidually or as a mixture, have the potential to be highly
useful tools to study anti-CMV antibody changes during
the course of disease. Validation of this approach, with
studies directed at monitoring CMV infection and reacti-
vation following blood transfusion using longitudinal
and larger sample numbers, are currently underway.
Materials and methods
Patient plasma
A first (n = 46 blinded sera) and second (n = 70) serum
sets were provided as coded samples for testing with LIPS.
The code was broken only after titers were established and
categorization of CMV infection status had been made.
Sera were kept at -80°C, aliquoted, and stored at 4°C. TheVirology Journal 2009, 6:45 http://www.virologyj.com/content/6/1/45
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sera were tested with IgG CMV Immunoassay (Focus
Diagnostics, Cypress, CA) for CMV seropositive and
seronegative status. The ELISA was considered the "stand-
ard" and sensitivity and specificity were determined based
on ELISA results.
Generation of Ruc-antigen fusion proteins
A mammalian Renilla luciferase (Ruc) expression vector,
pREN2, was used to generate all plasmids. CMV protein
fragments were amplified by PCR with gene specific
linker-primer adapters: Four different protein fragments
were amplified from CMV genomic DNA including
pp150-d1 (aa 502–692), pp150-d2 (aa 859–1048), pp65-
d1 (aa 2–295), and pp65-d2 (aa 312–561). In each case,
the cDNA fragments were subcloned downstream of Ruc
and a stop codon was inserted directly after the CMV pro-
tein coding sequence. The CMV sequence in each plasmid
construct was confirmed by DNA sequencing. Details of
the nucleotide and amino acid sequences can be found in
the GenBank database with accession numbers FJ705802,
FJ705803, FJ705804, and FJ705805 for pp150-d1, pp150-
d2, pp65-d1, and pp65-d2, respectively. PCR primer
sequences used to generate each construct are available
upon request.
Fusion proteins for these four different protein fragments
were generated by transfecting Cos-1 cells with individual
Ruc expression vectors using Fugene-6. Forty-eight hours
later the Cos1 cells were washed once with PBS and then
scraped and sonicated on ice in lysis buffer (20 mM Tris,
pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100
and 50% glycerol, and protease inhibitors (Complete
Mini protease inhibitor cocktail tablets, Roche Diagnos-
tics, Indianapolis, IN). The lysates were twice centrifuged
at 13,000 × g, supernatants collected and then stored at -
20°C until use. The activities of the lysates (light units
(LU)/ml) were next determined using a single tube lumi-
nometer (20/20 from Turner Scientific) with a coelentera-
zine substrate mix (Promega, Madison, WI).
LIPS analysis
LIPS assays were performed at room temperature using a
96-well plate format. Master plates were constructed by
diluting patient plasma 1:10 in assay buffer A (20 mM
Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-
100) in 96-well polypropylene microtiter plates. To quan-
tify antibody titers by LIPS, 40 μl of buffer A, 10 μl of
diluted human plasma (1 μl equivalent), and 50 μl of 1 ×
107  light units (LU) of Ruc-antigen Cos1 cell extract,
diluted in buffer A, were added to each well of polypropyl-
ene plates and incubated for 1 hour at room temperature.
Next, 7 μl of a 30% suspension of Ultralink protein A/G
beads (Pierce Biotechnology, Rockford, Illinois, USA) in
PBS was added to the bottom of each well of a 96-well fil-
ter HTS plate (Millipore, Bedford, Massachusetts). The
100 μl antigen-antibody reaction mixture was then trans-
ferred to filter plates and incubated for 1 hour at room
temperature on a rotary shaker. Proteins bound to the
protein A/G beads were washed 10 times with buffer A
and twice with PBS using a BioMek FX work station (Beck-
man Coulter, Fullerton, California, USA) with an inte-
grated vacuum manifold. After the final wash, LU were
measured in a Berthold LB 960 Centro microplate lumi-
nometer (Berthold Technologies, Bad Wilbad, Germany)
using coelenterazine substrate mix (Promega, Madison,
Wisconsin, USA). All of the LU data shown represent the
average of two independent experiments and have been
corrected for background LU values of Ruc Cos-1 cell
extract added to protein A/G beads, but not incubated
with plasma.
For the four antigen mixture tests, the assay was modified
slightly. In these tests, each of the 4 antigen extracts (1 ×
107 LU per antigen) were added to each well and proc-
essed as described above.
Statistical analysis
GraphPad Prism software (San Diego, California, USA)
was used for statistical analyses, including evaluating test
performance by area under the curve (AUC). Results for
quantitative antibody titers between uninfected controls,
CMV-positive samples were reported as the geometric
mean ± the 95% confidence interval. Mann-Whitney U
tests were used for comparison of antibody titers in differ-
ent groups and the level of significance was set at P < 0.05.
Correlations between different antibody titers were
assessed by Spearman correlation coefficient. For the cal-
culation of sensitivity and specificity, a simple statistically
based cut-off limit for each antigen was derived from the
mean value of the uninfected samples plus 5 standard
deviations.
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